Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 4 (6), 593-605

Comparative Efficacy and Safety of Daclatasvir/Asunaprevir Versus IFN-based Regimens in Genotype 1b Hepatitis C Virus Infection

Affiliations
Review

Comparative Efficacy and Safety of Daclatasvir/Asunaprevir Versus IFN-based Regimens in Genotype 1b Hepatitis C Virus Infection

James E Signorovitch et al. J Comp Eff Res.

Abstract

Aim: Efficacy and safety comparison of daclatasvir/asunaprevir (DCV + ASV) versus peginterferon-α/ribavirin (A/R) alone or combined with telaprevir, boceprevir, simeprevir or sofosbuvir in chronic genotype 1b hepatitis C virus infection.

Methods: Network meta-analysis (NMA) and matching-adjusted indirect comparisons (MAICs).

Results: Among treatment-naive patients, DCV + ASV demonstrated higher sustained virologic response (SVR) rates than telaprevir + A/R, boceprevir + A/R and A/R in NMA and MAICs and simeprevir + A/R in NMA. DCV + ASV among treatment-experienced patients had higher SVR rates than telaprevir + A/R, boceprevir + A/R, simeprevir + A/R and A/R in MAICs. DCV + ASV had lower adverse events rates than comparators.

Conclusion: DCV + ASV demonstrated superior efficacy and safety compared with A/R-based regimens.

Keywords: asunaprevir; daclatasvir; direct-acting antiviral agents; genotype 1b; hepatitis C.

Similar articles

See all similar articles

Cited by 2 PubMed Central articles

Publication types

MeSH terms

LinkOut - more resources

Feedback